Fluorescence lifetime-based FRET biosensors for monitoring N-terminal domain interactions of TDP-43 in living cells: A novel resource for ALS and FTD drug discovery

Noah Nathan Kochen,Marguerite Murray,Nagamani Vunnam,Elly E. Liao,Lihsia Chen,Anthony R Braun,Jonathan N. Sachs

DOI: https://doi.org/10.1101/2024.10.11.617905

2024-10-12

Abstract:TAR DNA-binding protein 43 (TDP-43) pathological aggregates are widely implicated in Alzheimer's disease, frontotemporal dementia and amyotrophic lateral sclerosis. While therapeutic platforms targeting TDP-43 have predominantly targeted its aggregation, recent findings suggest that loss of functional TDP-43 dimers and multimers - essential for RNA processing - occur upstream of aggregation and is driven through disruption of N-terminal domain (NTD) interactions. Here, we demonstrate that these interactions are targetable via cellular fluorescence lifetime-based FRET biosensors which we used to screen the FDA-approved Selleck library. Our NTD-specific hit ketoconazole rescues sorbitol-induced TDP-43 mislocalization and aggregation, and ameliorates TDP-43 induced downregulation of SREBP2, a TDP-43 mRNA binding target with known implication in ALS. In addition, ketoconazole improves neurite outgrowth in a TDP-43 overexpressing neuron model and motor dysfunction in TDP-43 overexpressing C. elegans. Taken together, our platform represents a novel approach for targeting NTD-dependent TDP-43 interactions, and the identification of ketoconazole validates an exciting translational premise for TDP-43 drug discovery.

Neuroscience

What problem does this paper attempt to address?

The problem that this paper attempts to solve is related to the pathological aggregation of TAR DNA - binding protein 43 (TDP - 43) associated with Alzheimer's disease (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Although most current treatment strategies focus on inhibiting the aggregation of TDP - 43, recent studies have shown that the loss of TDP - 43 functional dimers and multimers occurs prior to aggregation and is driven by the disruption of N - terminal domain (NTD) interactions. Therefore, this paper aims to develop a new treatment method. By using fluorescence - lifetime - based FRET (fluorescence resonance energy transfer) biosensors to monitor the interactions of the TDP - 43 N - terminal domain in living cells, small molecules that can stabilize these interactions are screened. Specifically, the researchers designed a series of fluorescence - lifetime (FLT) FRET biosensors in living cells. These biosensors can distinguish between NTD - dependent and non - NTD - dependent TDP - 43 homo - / self - assemblies. Through these biosensors, they screened the FDA - approved Selleck compound library and identified ketoconazole, a known P450 cytochrome inhibitor, which can increase the FRET signal of TDP - 43 in an NTD - dependent manner. Further studies have shown that ketoconazole can rescue the reduction in neurite growth caused by TDP - 43 overexpression, the cytoplasmic mislocalization and aggregation of TDP - 43 induced by hyperosmotic stress, and the down - regulation of SREBP2 caused by TDP - 43 overexpression. SREBP2 is a key regulator of the cholesterol biosynthesis pathway related to ALS. In conclusion, this study not only provides a new method to monitor and target the interactions of the TDP - 43 N - terminal domain, but also validates the effectiveness of ketoconazole as a potential drug for treating TDP - 43 - related diseases.

Fluorescence lifetime-based FRET biosensors for monitoring N-terminal domain interactions of TDP-43 in living cells: A novel resource for ALS and FTD drug discovery

Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD

Transcriptome-based screening in TARDBP/TDP-43 knock-in motor neurons identifies the NEDD8-activating enzyme inhibitor MLN4924

Using Tetracysteine-Tagged TDP-43 with a Biarsenical Dye To Monitor Real-Time Trafficking in a Cell Model of Amyotrophic Lateral Sclerosis

Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice

A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy

Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis models

Novel in vivo TDP-43 stress reporter models to accelerate drug development in ALS

Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors

Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD

TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia

Emerging perspectives of synaptic biomarkers in ALS and FTD

Molecular Visualization of Neuronal TDP43 Pathology In Situ

A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD

A transient protein folding response targets aggregation in the early phase of TDP-43-mediated neurodegeneration

Development of a Sensitive and Reliable Meso Scale Discovery-Based Electrochemiluminescence Immunoassay to Quantify TDP-43 in Human Biofluids

NMR Fragment-Based Screening Against Tandem RNA Recognition Motifs of TDP-43.

A TDP-43 acetylation-mimic mutation that disrupts RNA-binding drives FTLD-like neurodegeneration in a mouse model of sporadic TDP-43 proteinopathy

Unveiling therapeutic biomarkers and druggable targets in ALS: An integrative microarray analysis, molecular docking, and structural dynamic studies

CRISPR interference to evaluate modifiers of C9ORF72-mediated toxicity in FTD